<DOC>
	<DOCNO>NCT01043094</DOCNO>
	<brief_summary>This Phase 4 , multicenter , open label , 1 period study . A total 16 subject plan ( 8 subject Group A 8 subject Group B ) : The 2 group comparable term age , gender , body mass index ( BMI ) ; range comparison obtain pooled demographic data renally impaired subject . The mean age Group B within 5 year mean age Group A , mean BMI Group B within 18 % mean BMI Group A , ratio men woman Group B Group A .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetic Single Dose Pitavastatin 4 mg Severe Renal Patients Versus Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Subject adult male female subject age 18 year old . Females childbearing potential must negative pregnancy test beginning study . Subject clinically significant medical condition ( renal impairment associate disease , hypertension , diabetes , dyslipidemia , subject Group A ) determine medical history , physical examination , 12lead ECG , clinical laboratory result ( hematology , serum chemistry , urinalysis [ able pas urine ] ) , serology result ( hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency virus type 1 2 antibody ) . Subjects positive result hepatitis C virus normal liver enzymes exclude . Any subject impair hepatic function potentially affect drug metabolism exclude . Subject provide write informed consent studyspecific evaluation perform . Subject able willing comply protocol study procedure . Subject maintenance hemodialysis . Subject BMI &gt; 37 kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>